Insight

Elisa Agostinetto: Drug-drug interactions between palbociclib and PPI in breast cancer

Elisa Agostinetto/X

Jan 5, 2025, 18:21

Elisa Agostinetto: Drug-drug interactions between palbociclib and PPI in breast cancer

Elisa Agostinetto, Medical Research Fellow at the University Hospital of Brussels, shared a post on LinkedIn:

“What is the impact of drug-drug interactions between palbociclib and proton pump inhibitors (PPI) in breast cancer?

Can PPI use explain why the PALLAS trial was negative?

Now out in ESMO our analysis of PALLAS exploring this question.”

Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109)

Authors: E. Agostinetto, G. Pfeiler, D. Hlauschek, E.L. Mayer, M. Lambertini, E. de Azambuja, M. Bellet-Ezquerra, J.L. Meisel, G. Rubovszky, N. Zdenkowski, Y. Novik, M. Ruiz-Borrego, K.A. Gelmon, E.P. Mamounas, H. Iwata, D.R. Lu, L. Soelkner, C. Fesl, M. Gnant, A. DeMichele

Elisa Agostinetto: Drug-drug interactions between palbociclib and PPI in breast cancer

A DeMichele Breast Cancer C. Fesl cancer D. Hlauschek D.R. Lu E. Agostinetto E. de Azambuja E.L. Mayer E.P. Mamounas Elisa Agostinetto G. Pfeiler G. Rubovszky H. Iwata J.L. Meisel K.A. Gelmon L. Soelkner M. Bellet-Ezquerra M. Gnant M. Lambertini M. Ruiz-Borrego N. Zdenkowski OncoDaily Oncology palbociclib PALLAS trial Y. Novik

FDA Priority Review Granted for TAR-200 After 82% Complete Response in BCG-Unresponsive Bladder Cancer

Paolo Tarantino: AACR Journals' Power Move for Reviewers

Best Immunotherapy Highlights from ESMO TAT ASIA 2025 You Shouldn't Miss

Oncologist Near Me – Nagashree Seetharamu: A Journey of Healing, Mentorship, and Leadership

Mohit Manrao: FDA Grants Priority Review for sBLA in Resectable Early-Stage Gastric and GEJ Cancers